PulseAugur
EN
LIVE 17:34:30
ENTITY Mike Doustdar

Mike Doustdar

PulseAugur coverage of Mike Doustdar — every cluster mentioning Mike Doustdar across labs, papers, and developer communities, ranked by signal.

Show in brief
Total · 30d
1
2 over 90d
Releases · 30d
0
0 over 90d
Papers · 30d
0
0 over 90d
TIER MIX · 90D
TOPICS
SENTIMENT · 30D

1 day(s) with sentiment data

RECENT · PAGE 1/1 · 2 TOTAL
  1. RESEARCH · CL_186524 ·

    Novo Nordisk faces growth challenges after Wegovy success, rival Eli Lilly gains ground

    Novo Nordisk, once Europe's most valuable company due to the success of its weight-loss drugs Ozempic and Wegovy, is facing challenges in developing new blockbuster treatments. Its rival, Eli Lilly and Company, has gain…

  2. COMMENTARY · CL_76638 ·

    Novo Nordisk CEO eyes longevity and aesthetics beyond weight loss drugs

    Novo Nordisk's CEO, Mike Doustdar, is exploring new therapeutic areas beyond weight loss and diabetes, including longevity and aesthetic medicine. The company is investigating semaglutide's potential to protect vital or…